Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older

Sydney George (), Justin Carrico, Katherine A. Hicks, Dessi Loukov, Cheryl Ng, Jessica Regan and Nikolaos Giannelos
Additional contact information
Sydney George: GSK
Justin Carrico: RTI Health Solutions
Katherine A. Hicks: RTI Health Solutions
Dessi Loukov: GSK
Cheryl Ng: GSK
Jessica Regan: GSK
Nikolaos Giannelos: GSK

PharmacoEconomics - Open, 2024, vol. 8, issue 5, No 14, 785-785

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00502-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00502-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00502-w

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().